All In Biotech

NDA 201532 · Eisai INC

Halaven

Eribulin Mesylate · Intravenous

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Sep 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Nov 15, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

245

59 Phase 3, 40 recruiting

FAERS reports

3,739

3,465 serious, 663 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 13, 2022 Supplement 23 · Efficacy · priority review LetterLabel
  • Jan 28, 2016 Supplement 15 · Efficacy · priority review OrphanLetterLabel
  • Nov 15, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • HALAVEN · ERIBULIN MESYLATE 1MG/2ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Eribulin" as an intervention, any sponsor and status, largest first.

All 245 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia538
  • malignant neoplasm progression383
  • febrile neutropenia331
  • myelosuppression318
  • pyrexia216
  • neuropathy peripheral214
  • leukopenia208
  • interstitial lung disease181
  • white blood cell count decreased177
  • neutrophil count decreased171
  • fatigue159
  • nausea157

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
201174
2012247
2013213
2014161
2015334
2016383
2017354
2018281
2019255
2020196
2021243
2022273
2023337
2024189
2025120
202678

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Halaven (Eribulin Mesylate)

2024 spending

$281K

Beneficiaries

14

40 claims

Per beneficiary

$20,076

$682.18 per unit

View as table
YearSpending
2020$1,193,528
2021$870,082
2022$865,201
2023$618,194
2024$281,060

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 190 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.